DataMeds AI, Inc.
corporate_fare Company Profile
DataMeds AI, Inc. (NASDAQ:MEDS) is a publicly traded company in the Trade & Services sector. Wiseek has independently scored 24 items for MEDS at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- DataMeds AI Reports Q2 Revenue Beat, $18.4M Loss, and $6.5M Funding
- DataMeds AI Reports $26.1M Loss, Going Concern Doubt, and Nasdaq Equity Deficiency
- DataMeds AI Registers 34.5M Shares for Resale — Potential 92% Dilution from May 2026 Toxic Convertible Deal
- DataMeds AI Inks LOI for Transformative Reverse Merger with EOS, Scilex, Datavault, and HBA
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$23.34M
Net Income
-$101.27M
Diluted EPS
-$1.43
Op. Cash Flow
-$10.86M
Gross Profit
-$6.43M
Operating Income
-$93.75M
Cash & Equivalents
$42.57K
Total Debt
$23.49M
Debt / Equity
-1.89×
Net Margin
-433.9%
Shares Outstanding
101.31M sh
Source: 10-K · filed 2026-04-24 · accession 0001493152-26-018958
show_chartPrice Chart
Loading chart...
feed MEDS - Filings & News (Page 2)
MEDS
Aug 18, 2026, 7:43 AM EDT
Price at Filing:
$1.50
Real-time Price:
$1.55
Change:
+$0.050 (+3%)
Market Cap:
$7.662M
MEDS
Aug 17, 2026, 6:05 AM EDT
Price at Filing:
$1.50
Real-time Price:
$1.55
Change:
+$0.050 (+3%)
Market Cap:
$7.662M
MEDS
Aug 07, 2026, 5:23 PM EDT
Price at Filing:
$2.01
Real-time Price:
$1.55
Change:
-$0.460 (-23%)
Market Cap:
$7.662M
MEDS
Aug 04, 2026, 4:30 PM EDT
Price at Filing:
$3.17
Real-time Price:
$1.55
Change:
-$1.62 (-51%)
Market Cap:
$7.662M